What is Terazosin?
Terazosin is an active ingredient used for the treatment of benign prostatic hyperplasia and high blood pressure (BPH). The product ingredients are: Terazosin hydrochloride (hcl) and Terazosin hydrochloride hydrate.
The brand name of Terazosin in United States is Hytrin.
Terazosin Mechanism of Action (MOA)
It produces a blockage of alpha1 adrenergic receptors in the prostate, bladder neck and prostatic capsule improving urodynamic profile in men with symptoms of benign prostatic hyperplasia. It also causes a decrease in systolic and diastolic pressure in the supine and standing position.
Therapeutic Indications and Dosage of Terazosin
Adults: Individualized dose:
– Symptomatic treatment of benign prostatic hyperplasia: initial 1 mg/night, increase to 2 mg after 3-4 days and increase until desired response; maintenance: 5 mg/day. Maximum 10 mg/day.
– Essential, mild or moderate high blood pressure: initial: 1 mg/night, double dose at weekly intervals; maintenance: 1-5 mg/day.
Maximum 20 mg/day.
Mode of administration
Oral use: Tablets or capsules of 1 mg, 2 mg, 5 mg and 10 mg.
Administer the first dose at bedtime, with or without food. If treatment is interrupted for several days, therapy should be started according to the initial regimen of administration.
Hypersensitivity, history of syncope during urination.
Warnings and precautions with Terazosin
- Risk of hypotension (first dose effect).
- Concomitance with antihypertensives (reduce or adjust antihypertensives and/or adjust terazosin doses).
- Risk of intraoperative flaccid iris syndrome during cataract surgery.
- Not recommended for children.
Pregnancy and Terazosin
There are no adequate controlled studies in pregnant women.
It is not known whether this active ingredient is excreted in breast milk.
Effects on driving ability
This active ingredient may cause drowsiness, so it should be administered with caution to patients who must drive or operate heavy machinery.
Adverse reactions and side effects of Terazosin
Palpitations, postural hypotension, syncope, tachycardia.
Nausea; peripheral edema, weight gain.
Fainting, vertigo, decreased libido, drowsiness.
Dyspnea, nasal congestion, rhinitis; impotence; blurred vision.
⭐⭐⭐⭐⭐ VIDEO OF TERAZOSIN/HYTRIN (DRUG)
Source: The content of this active ingredient has been written taking into account the clinical and molecular information of all medicines authorised and marketed in the United States under the Unique Ingredient Identifier (UNII) by the Substance Registration System (SRS) of the Food and Drug Administration (FDA) and the United States Pharmacopeia (USP).
In order to know in detail the information authorized by the FDA for each drug, you should consult the corresponding medication guide authorized by the FDA.